Form 4: Medtronic Executive Michelle Quinn Receives Significant Equity Grants

Medtronic plc's EVP, General Counsel, and Secretary, Michelle Quinn, was granted a substantial package of restricted stock units, performance share units, and stock options, aligning her compensation with future company performance.

Summary

• Michelle Quinn, EVP, GC and Secretary of Medtronic plc, received equity compensation grants on July 28, 2025.
• Grants include 5,437 restricted stock units (RSUs) vesting 100% on the third anniversary of the grant date.
• An additional 16,310 restricted stock units (RSUs) were granted, vesting in three annual installments starting one year from the grant date.
• 13,592 performance share units (PSUs) were granted, with the number of shares issued contingent on achieving certain performance metrics over a three-year period ending April 28, 2028; target issuance is 13,592 shares, maximum is 27,184 shares, and minimum is 0 shares.
• 38,336 stock options were granted with an exercise price of $91.97, becoming exercisable at a rate of 25% per year beginning on the first anniversary of the grant date and expiring on July 28, 2035.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation grants to a key executive, which is generally positive for aligning management incentives with shareholder interests and executive retention. It does not contain any negative operational or financial news.

Positives

• The grants of restricted stock units, performance share units, and stock options align executive compensation with shareholder interests and long-term company performance.
• Equity awards serve as a retention mechanism for key executives.

Risks

• The value of restricted stock units and stock options is subject to the future performance of Medtronic's stock price.
• Performance share units are contingent on specific performance metrics being achieved, meaning the actual number of shares received could be zero if minimum targets are not met.
• Stock options carry the risk that the stock price may not exceed the exercise price of $91.97, rendering them worthless.

Future Outlook

The grants indicate a long-term incentive structure for Michelle Quinn, with vesting periods extending several years into the future and performance share units tied to metrics through April 2028. The stock options have an expiration date of July 28, 2035, suggesting a long-term view on stock performance.

Industry Context

The granting of restricted stock units, performance share units, and stock options is a standard practice for executive compensation in large, publicly traded companies, particularly in the medical technology and healthcare industry. This structure aims to incentivize long-term performance and align executive interests with those of shareholders.

Comparison to Industry Standards

• The mix of time-based restricted stock units and performance-based share units, alongside stock options, is a common and well-established compensation structure for senior executives in global medical device companies like Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Stryker Corporation (SYK).
• The vesting schedules (e.g., three-year cliff for some RSUs, annual installments for others, and three-year performance period for PSUs) are typical for retaining talent and encouraging sustained performance, comparable to practices seen at peers.
• The stock option exercise price being set at the grant date's market price (implied by $0 acquisition cost for the option itself) is standard.

Stakeholder Impact

• Shareholders: The equity grants aim to align the interests of the EVP, GC and Secretary with shareholders by tying a significant portion of her compensation to the company's stock performance and achievement of strategic goals.
• Employees: While not directly impacting all employees, such executive compensation structures can set a precedent for broader employee incentive programs.

Next Steps

• Vesting of 5,437 restricted stock units on the third anniversary of July 28, 2025.
• Annual vesting of 16,310 restricted stock units beginning one year from July 28, 2025.
• Assessment of performance metrics for performance share units by April 28, 2028, determining the final number of shares to be issued.
• Stock options becoming exercisable at 25% per year beginning one year from July 28, 2025.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation grants to a senior executive. While these grants align management incentives with shareholder interests, they do not provide new material information about the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. It is a standard disclosure for executive compensation.

Keywords

Medtronic, MDT, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Performance Share Units, Stock Options, Executive Compensation, Corporate Governance